Syndax Pharmaceuticals, Inc. (SNDX) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-26

Business type: Asset play

How it makes money

It earns revenue by selling its approved cancer therapies and receiving collaboration and milestone payments from its partner.

It generates product revenue from sales of Revuforj and collaboration as well as milestone revenue from sales of Niktimvo. Profitability depends on the successful commercialization of these medicines in the United States and other markets, overcoming pricing and reimbursement hurdles, and managing ongoing operating expenses as it advances its clinical pipeline.

What protects it: the moat

It relies on regulatory approvals, first-mover advantages, and intellectual property protection to defend its market position.

Management asserts that its first-in-class therapies, robust clinical data, and proprietary rights safeguard its commercial standing against competing biotechnology and pharmaceutical companies. However, maintaining this advantage requires continued success in clinical development and defending against competitors attempting to enter the same therapeutic areas.

What growth costs

It reinvests heavily in research, clinical development, and commercialization efforts to expand its product pipeline and support future growth.

The filing does not provide a rigid split between maintaining existing operations and funding growth, but it notes substantial ongoing investments in research and development, clinical trials, and commercial sales infrastructure for its approved medicines and pipeline candidates.

What could damage it

If its collaboration partner Incyte deprioritizes or fails to perform under the agreement, its commercialization of axatilimab could be severely impaired.

The company relies closely on Incyte for the commercialization and further development of axatilimab. If Incyte fails to fulfill its obligations or shifts its investment focus elsewhere, the development and sales timelines for the product would suffer, directly damaging the company's expected collaboration revenues.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Other companies in Biotechnology